Summit Therapeutics (SMMT) statistics

Analysts' price targets and ratings, ownership, short interest, trading figures and dates for Summit Therapeutics, as the data feed reports them.

Analysts' mean target, 13 analysts
$29.46
176.1% above the price

The 13 analysts reported by the data feed have a mean price target for Summit Therapeutics of $29.46, 176.1% above the $10.67 price (range $11.72–$42.96). 26.67% of the float was sold short as of Oct 30, 2026. Institutions hold 17.2% of the shares and insiders 80.7%. Source: Yahoo Finance, read Nov 17, 2026.

Key facts

Analysts' mean target
$29.46+176.1% vs price
Analysts
13
Short interest
26.67%of float, Oct 30, 2026
Short ratio
7.56 days
Institutions
17.2%
Insiders
80.68%
Beta
-1.52

Figures read . Source: Yahoo Finance (quoteSummary: key statistics, financial data, recommendation trend, major holders, insider purchases, calendar events). Analysts' targets and ratings, ownership and short interest are the data feed's figures and can lag the filings and exchange reports they come from. Figures, not advice.

Analysts' consensus as reported by the data feed

13 analysts covering Summit Therapeutics, as the data feed counts them. Price targets and ratings are other people's estimates — not facts about the company, and not advice. Distances are from the latest price the feed gave with these figures, $10.67.

Analysts' price targets for Summit Therapeutics
Mean price target$29.46176.1% above the price (+176.1%)
Median price target$32.62205.7% above the price (+205.7%)
Highest target$42.96302.6% above the price (+302.6%)
Lowest target$11.729.8% above the price (+9.8%)
Analysts with a target13

Ratings this month · 16 analysts

Strong buy 1(6%)Buy 10(63%)Hold 5(31%)
Analysts' ratings of Summit Therapeutics this month, by rating
RatingAnalystsShare
Strong buy16%
Buy1063%
Hold531%
Sell00%
Strong sell00%

The feed averages these to 1.69 on its scale of 1 (strong buy) to 5 (strong sell), which it labels “buy”.

Who owns Summit Therapeutics

Ownership of Summit Therapeutics
Held by institutions17.2%386 institutions; percent of shares outstanding
Held by institutions, of the float88.8%
Held by insiders80.68%percent of shares outstanding
Shares outstanding799.76M
Float154.3Mshares available to trade
Insiders' net purchases, six months00 purchases (0 shares), 0 sales

Percentages are of shares outstanding unless the row says float. Insiders' net purchases are shares bought minus shares sold by insiders, as the data feed totals their reported trades.

Short interest as reported by the data feed

Shares sold short and not yet covered, as of Oct 30, 2026. Short interest is counted twice a month, so this is not today's figure.

Short interest in Summit Therapeutics
Shares short42.26Mas of Oct 30, 2026
Percent of float26.67%shares short ÷ float
Percent of shares outstanding5.28%shares short ÷ shares outstanding
Short ratio (days to cover)7.56shares short ÷ average daily volume

Summit Therapeutics short interest from FINRA, with its history

Trading figures

Trading figures for Summit Therapeutics
Beta-1.52movement against the market; 1 moves with it
52-week high$29.23
52-week low$10.53
Average volume, 3 months6.4Mshares a day
Average volume, 10 days7.15Mshares a day

Questions and answers

What is the analysts' price target for Summit Therapeutics (SMMT)?

As reported by the data feed, the mean price target of the 13 analysts covering Summit Therapeutics is $29.46, 176.1% above the latest price of $10.67. The highest target is $42.96 and the lowest $11.72. Targets are analysts' estimates, not facts about the company and not advice.

How do analysts rate Summit Therapeutics stock?

Of the 16 ratings the data feed reports for the current month, 1 are strong buy, 10 buy, 5 hold, 0 sell and 0 strong sell.

How many Summit Therapeutics shares are sold short?

As reported by the data feed, 42.26M shares were sold short, 26.67% of the float as of Oct 30, 2026. At the average daily volume that is 7.56 days to cover. Short interest is reported twice a month; it is not today's figure.

Who owns Summit Therapeutics stock?

As reported by the data feed, institutions hold 17.2% of the shares (386 institutions) and insiders 80.7%. There are 799.76M shares outstanding, of which 154.3M are in the float.

How much does Summit Therapeutics stock move with the market?

Its beta, as reported by the data feed, is -1.52: a beta above 1 means the share has tended to move more than the market, below 1 less. Over the past 52 weeks it traded between $10.53 and $29.23.

Cite this page

Funkfolio, “Summit Therapeutics (SMMT) statistics and analyst targets”, data as of 17 November 2026. https://funkfolio.com/stock/SMMT/statistics

Underlying data: Yahoo Finance.